Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

Click to increase image sizeClick to decrease image size

Acknowledgments

We thank the patients and the investigators, institutions, and their staff for their support. We thank James E. Bradner (Harvard Medical School and Dana-Farber Cancer Institute, USA) for expert discussion on HDAC and proteasome inhibition and enthusiastic support for this clinical study concept. The authors thank Dina Marenstein, PhD, of Chameleon Communications International and William Fazzone, PhD, of Articulate Science for editorial support funded by Novartis Pharmaceuticals.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.